Radiolabelled Aptamers for Theranostic Treatment of Cancer
Cancer has a high incidence and mortality rate worldwide, which continues to grow as millions of people are diagnosed annually. Metastatic disease caused by cancer is largely responsible for the mortality rates, thus early detection of metastatic tumours can improve prognosis. However, a large numbe...
Saved in:
Main Authors: | Umair Khalid (Author), Chris Vi (Author), Justin Henri (Author), Joanna Macdonald (Author), Peter Eu (Author), Giovanni Mandarano (Author), Sarah Shigdar (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2018-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aptamer-Based Diagnostics and Therapeutics
by: Sarah Shigdar
Published: (2019) -
Immune Checkpoint Inhibitor-Mediated Cancer Theranostics with Radiolabeled Anti-Granzyme B Peptide
by: Carolina de Aguiar Ferreira, et al.
Published: (2022) -
Production, purification, and radiolabeling of the 203Pb/212Pb theranostic pair
by: Brooke L. McNeil, et al.
Published: (2021) -
Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging
by: Leila Hassanzadeh, et al.
Published: (2018) -
Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof
by: Sarah Shigdar, et al.
Published: (2021)